Table 3.

Adjusted ORs and 95% CIs for rectal cancer (NCCCS II) by insulin use and race

Began insulin use ≥1 y ago* (n = 307)
Duration of insulin use ≥1 y (n = 293)
Duration of insulin use ≥2 y (n = 287)
n casesn controlsOR (95% CI)n casesn controlsOR (95% CI)n casesn controlsOR (95% CI)
White, no insulin use76751.0076751.0076751.00
African American, no insulin use36300.76 (0.40-1.46)36300.73 (0.37-1.42)36300.74 (0.38-1.44)
White, insulin use40261.74 (0.92-3.31)35202.11 (1.05-4.23)34162.53 (1.21-5.28)
African American, insulin use13110.94 (0.33-2.71)1381.46 (0.46-4.61)1371.81 (0.55-6.00)
  • NOTE: ORs were adjusted for age (5-y age groups), sex (male, female), NSAID use (never, occasional, frequent), calcium intake (quartiles), family history of colorectal cancer (yes, no), education (high school degree or less, some college, college degree, or more), and offset.

  • * Analysis includes all subjects except those that began insulin treatment <1 y before diagnosis (or cases) or interview (for controls).

  • Analysis includes all subjects except for those that used insulin therapy for <1 y.

  • Analysis includes all subjects except for those that used insulin therapy for <2 y.